Background: Chronic intestinal pseudo-obstruction (CIPO) represents the most severe form of gastrointestinal dysmotility with debilitating and potentially lethal consequences.
These studies most likely underestimates the true number of new cases per year, as they do not include patients who develop symptoms of CIPO later in life. In another survey of 378 institutions belonging to the Japanese Society of Gastroenterology, CIPO prevalence in adult patients was estimated to be 1.0 and 0.8 cases per 100 000 males and females respectively. The incidence in the same population was 0.21 and 0.24 cases per 100 000 males and females respectively. 13 The purpose of this article is to provide a broad review of CIPO ranging from pediatric to adult age highlighting selectively the main clinical aspects such as symptoms/signs, diagnosis and therapeutic options in the different age groups. Deliberately, we did not address the putative mechanisms underlying severe gut dysfunction and the attendant histopathological features and the reader is referred to published comprehensive articles on these topics (references . In Table 1 we have summarized the classification of CIPO in relation to etiopathogenetic factors.
| DISEASE SPECTRUM
Chronic intestinal pseudo-obstruction is not a single clinical entity, rather an umbrella term for a range of different diseases leading to severe, end-stage gut motor failure. The most severe cases of the CIPO spectrum are those involving pediatric patients with antenatal (in utero) evidence of multivisceral dilation of the hollow viscera (e.g. digestive and urinary systems), often characterized by inability to tolerate enteral feeding and poor prognosis ( Fig. 1A and B) . 8, [58] [59] [60] This clinical subset represents the most common group of pediatric CIPO patients with diffuse involvement of the GI tract. In these cases, the neuromuscular abnormalities (either genetic or acquired) of the GI tract do not preclude birth, but can be severe enough to generate the onset of symptoms in the early newborn period with reported mortality rates ranging from 10% to 32%. 8, 58, 59 More rarely, some cases appear to be acquired after birth being characterized by a variable period of normality followed by progression to intestinal failure with bowel (and often urinary tract) dilatation.
In some of the most aggressive forms of acquired CIPO, the histopathological analysis may detect a massive inflammatory (mainly lymphocytic) neuro-muscular infiltrate, reminiscent of the autoimmune pancreatic "insulitis" underlying insulin-dependent diabetes mellitus of the childhood 25 ( Fig. 1C and D) . These cases of CIPO may respond to an immunosuppressive treatment if the immune-mediated insult has not completely damaged regulatory cells, i.e. enteric nerves, interstitial cells of Cajal (ICC), and smooth muscle.
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Other cases of pediatric and adult CIPO may occur in patients who experience more insidious mild and non-specific symptoms (either "irritable bowel syndrome" -or "dyspepsia" -like) thought not to carry a risk to evolve into severe dysmotility. Nonetheless, some of these patients do progress on to a classic CIPO phenotype over time ( Fig. 1E and G). We consider them the "dark-side" of adult CIPO spectrum, i.e.
cases in which a number of factors, including an altered gut microbiota, intestinal epithelial barrier dysfunction, immune dysregulation, and other poorly defined mechanisms may operate, individually or in concert, to impair the neuro-muscular homoestasis. 6 Patients with acute onset of CIPO after abdominal surgery, i.e. mimicking a prolonged postoperative ileus, remain a largely unexplained subset. Other striking examples are those cases occurring after ileal bypass performed to treat morbid obesity, suggesting that surgical manipulation may by itself evoke neuro-myoelectrical abnormalities in predisposed alimentary tracts. 61 A synoptic view of this section is reported in Fig. 1 .
| CLINICAL FINDINGS
Chronic intestinal pseudo-obstruction may involve any segment of the GI tract and therefore symptoms can vary from patient to patient based on the location and the extent of the gut segment involved.
In addition, extra-intestinal manifestations and malnutrition contribute to the clinical features. 5, 7, 15, [62] [63] [64] 
Key Points
• There is no single diagnostic test or pathognomonic findings for CIPO. The main goals of the diagnostic work up are to exclude bowel mechanical obstruction, to identify underlying diseases and to understand the pathophysiological features.
• Treatment is challenging and requires a multidisciplinary effort.
• Key objectives in the management of patients with CIPO are to avoid unnecessary surgery, restore fluid and electrolyte balance, maintain an adequate caloric intake, promote coordinated intestinal motility, and treat bacterial overgrowth.
(80%) show clinical manifestations by the first year of age, while the remaining 20% have sporadic onset during the first two decades of life. 8, 9, 12, 58, 59 One study indicated that the median age of symptom onset in adults is 17 years.
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Both pediatric and adult CIPO shares many clinical aspects, although distinctive features can be identified (Table 2 ). In any age group, the clinical picture tends to be dominated by abdominal pain and distension (80%), which are particularly severe during acute episodes of pseudo-obstruction. 37 Associated symptoms include nausea and vomiting (75%), constipation (40%), and diarrhea (20%). 6, 10, 37 Between acute episodes, patients can be minimally symptomatic, or continue to experience severe proximal (anorexia, early satiety, nausea and vomiting) and distal digestive symptoms (constipation, diffuse abdominal pain and/or distension). 6, 8 Prevalence and severity of acute episodes that recur at irregular intervals vary from patient to patient.
Malnutrition is another significant clinical aspect in any patient with CIPO. This is due to both the limited oral intake, because ingestion of food generally aggravates symptoms, and the intestinal malabsorption related to the altered gut transit, often associated with dilated bowel loops. In about 30% of CIPO patients small intestinal bacterial over- The megacystis can be associated with a microcolon, a phenotype referred to as megacystis-microcolon-intestinal-hypoperistalsis syndrome. 4 Other syndromic form of CIPO are represented by the mitochondrial disorders which in a large adult series account for 19% of all CIPO patients. They are characterized by severe intestinal dysmotility, poor nutritional status, and neurological manifestations, e.g. peripheral neuropathy (with mild to moderate hypoesthesia), proprioceptive ataxia, progressive external ophthalmoplegia with ptosis, and hearing loss. 2 Gastrointestinal manifestations are common at presentation and positive family history together with the progressive neurological and nutritional deterioration should alert clinicians to search for mitochondrial disorders. 42, 43, 74, 75 Secondary systemic forms (i.e. related to underlying conditions)
of CIPO are more common in adult patients in whom they occur at much older age. 
| Radiology
A plain radiograph of the abdomen usually identifies the typical signs of intestinal obstruction, i.e. air-fluid levels and dilated bowel T A B L E 2 Main similarities and differences in CIPO in children and adults 
| Endoscopy
Upper GI endoscopy may be useful to exclude a mechanical occlusion of the proximal small intestine and to collect duodenal biopsies in cases where celiac disease or eosinophilic gastroenteropathy are suspected. 3 Colonoscopy can be used to rule out mechanical obstruction and decompress the large intestine, although this maneuver rarely provides long-term satisfactory results. 80 The wireless motility capsule measures intraluminal pH, temperature, and pressure; however, the role of this technique in the diagnosis of CIPO has not been established yet and its use is thought to be possibly hazardous when a mechanical obstruction has not been definitely ruled out. 
| Laboratory tests
Laboratory exams are aimed to uncover secondary causes of CIPO. 
| Manometry
Intestinal manometry can be useful to define the pathophysiological (neuro-muscular) mechanisms involved in CIPO (e.g. neuropathy or myopathy), although it has a low diagnostic specificity and in most pediatric and adult patients does not influence treatment. 
| NATURAL HISTORY
A severe clinical course can be expected for both pediatric and adult patients with CIPO when an underlying treatable disease is not identified. 6, [62] [63] [64] 71 In a single-center study of 59 adult patients with idiopathic CIPO followed up for a long time (13 years), it was demonstrated that the average time between the first sub-occlusive episode and the diagnosis of CIPO was 8 years, with 88% of patients undergoing an average of 3 unnecessary surgical procedures. 6 Similar rates of questionable surgery are seen in the pediatric setting. 59 The digestive symptoms worsened over time with abdominal pain becoming intractable or responsive only to major analgesics (e.g. opioids -always used parsimoniously and with extreme caution in our own experience) in approximately 25% of cases. 6 Most patients had oral feeding restrictions, while 30-50% of patients needed long-term PN. 6, 62, 63 A study by Amiot et al., which examined all patients with CIPO on PN at home, revealed that the lowest mortality was associated with the ability to restore oral feeding and with the presence of symptoms before 20 years of age, while an increased mortality was associated with the presence of scleroderma.
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Manometric parameters, such as inadequate or absent motor response to meals, absence of migrating motor complex (MMC) during fasting, and generalized hypomotility have been shown to be predictive of poor outcome in patients with CIPO. 62, 84 Finally, detection of esophageal dysmotility in CIPO seems to have negative prognostic implications in terms of mortality and need for home PN. 87 In children with CIPO, a myopathic etiology, coexisting urinary involvement, and concurrent intestinal malrotation are poor prognostic factors. 8 In both adults and children, the risk of death is increased by the absence of a specialist team and in the early phases after the diagnosis of intestinal failure has been established. In cases of inadequate oral intake, enteral nutrition with standard nonelemental formula may be considered. In children, extensively hydrolyzed and elemental formulas are often empirically used to facilitate intestinal transit and absorption. 4, 5, 92 Before a permanent feeding tube is placed, a trial with a nasogastric or nasojejunal feeding tube should be attempted using an enteral formula at a rate sufficient to provide an adequate caloric support. 91, 93, 94 When delayed gastric emptying is present, bypassing the stomach and directing the feeding into the small intestine is generally preferred. Jejunal feeding tubes were tolerated in all patients with manometrically detectable MMC vs 33% of those without. Enteral nutrition should be started with a slow infusion given continuously or, preferably, in a cyclical manner (during the night). encephalopathy, and 4 patients progressing to cirrhosis. 62 Oral intake was a major independent factor associated with better survival; thus, patients receiving PN should be allowed and encouraged to maximize oral intake as tolerated.
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| Pharmacological therapy
The main aim of pharmacological treatment in patients with CIPO is to promote GI propulsive activity, thereby improving oral feeding, decreasing symptom severity, and minimizing SIBO.
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The efficacy and main features related to various drugs, such as erythromycin, metoclopramide, domperidone, somatostatin analogues (octreotide and lanreotide), cholinesterases inhibitors (neostigmine and pyridostigmine), serotoninergic agents (such as 5-hydroxytryptamine receptor 4 -5-HT 4 -agonists, e.g. prucalopride), prostaglandins and gonadotropin-releasing hormone analogues (leuprolide), have been reported in a number of pediatric and adult CIPO studies (Table 3) .
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Erythromycin is a macrolide antibiotic mimicking the prokinetic hormone motilin that induces phase III of the MMC. It has shown to be effective (at a dose of 1.5-2 g/day in adults or 3-5 mg/kg/dose in children) in accelerating gastric emptying and improving symptoms of CIPO in case reports. 4, 96 Metoclopramide and domperidone are two orthopramides which exert their prokinetic effects via type 2 dopamine receptor antagonism and increasing acetylcholine release from myenteric neurons. Although widely used in patients with functional gut disorders, 7 there are no clinical data regarding their use in CIPO. In addition, metoclopramide has a boxed warning by the Food and Drug
Administration due to the risk of tardive dyskinesia. 97 Octreotide, a long-acting analogue of somatostatin, is known to evoke phase III of the MMC in the small intestine of patients with scleroderma-related CIPO. 98 Subcutaneous octreotide at a dose of 50 μg/day resulted in a significant beneficial effect by relieving bacterial overgrowth in those patients. 98 Further studies confirmed its efficacy showing reduction in nausea, vomiting, bloating, and abdominal pain, in a subset of idiopathic CIPO. 99 The acetylcholinesterase inhibitor neostigmine has proven efficacy in colonic decompression in adult and pediatric acute colonic pseudo-obstruction. 100 Repeated use was successful in an adult patient with colonic pseudo-obstruction, although chronic use in children with CIPO has not been reported. 101 The longer acting pyridostigmine has also been used with success in adult patients with CIPO. In CIPO characterized by histopathological signs of marked inflammation/immune response within myenteric ganglia or throughout the neuromuscular tract, immunosuppressive drugs (e.g., steroids and azathioprine), might be an effective therapeutic options. 34, 35, 38 Treatment of secondary forms of CIPO is mainly directed toward the underlying diseases (e.g., scleroderma, paraneoplastic syndrome, endocrine related disorders, and many others) in addition to gut-directed therapy such as antibiotics, prokinetics, and laxatives.
| Endoscopic and surgical therapy
Decompression of distended GI segments via intermittent nasogastric suction, rectal tubes, or endoscopy in both adults and children is an important therapeutic target. 2, 3, 113 In some cases a "venting" enterostomy, 114 typically placed endoscopically in the intestine, may be necessary. Recently, repetitive colonoscopic decompression has been successfully used as a bridge therapy before surgery in a pregnant woman with CIPO. 115 In adult patients needing multiple endoscopic decompression, percutaneous endoscopic colostomy has been recently proposed as a feasible therapeutic option as it leads to durable symptom relief without risk of surgical intervention.
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The role of surgery in CIPO has been debated over the years.
Although its use may be indicated as a tool to collect gut biopsy specimens for histopathology, the need for surgical therapy is sometimes required in emergency situations (massive bowel distension and perforation/ischemia). In a retrospective study on 63 adult patients there was an overall postoperative mortality rate of 7.9%, while CIPO-related re-operation rate was 66% at 5 years. 117, 118 In children palliative procedures such as feeding/venting gastrostomies and jejunostomies are mainly used to relieve symptoms in half of the patients. 9, 119, 120 It is important to keep in mind that when a surgical procedure is performed in a CIPO patient, full-thickness biopsies should be obtained and processed in dedicated centers. 
| Transplantation
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These data were also recently confirmed by an Italian study with a reported survival rate for recipient of intestinal grafts, in any combination, of 75% at 2-year follow-up. 130 Notably, the catch-up growth seen in children following liver transplantation has not been demonstrated in children with intestinal transplantation. This is probably related to the severity of the illness at the time of presentation and the use of intense immunosuppression, including long-term corticosteroids.
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Concerning extra-digestive organ transplant, the allogeneic he- 
| CONCLUSIONS
Chronic intestinal pseudo-obstruction is a rare and severe condition resulting in a marked impairment of GI motility with the appearance of a mechanical obstruction, without any detectable mechanical cause.
Although still a challenge for most clinicians and surgeons, the future of CIPO may be more promising than one would expect thanks to a number of important achievements. Firstly, less invasive diagnos- 
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LITERATURE EVALUATION FOR THE PRESENT REVIEW
A search was performed using Medline and Premedline from 1950 to June 2016. MeSH and free-text terms were chosen to negate problems of syntax, with six iterations of CIPO and children, diagnosis, therapy, comorbidities, natural history, incorporated. Search terms were "CIPO and children, diagnosis, therapy, comorbidities, natural history" OR "CIPO/diagnosis" OR "CIPO/natural history" OR "CIPO/ drug therapy" OR "CIPO/nutritional therapy" OR "CIPO/surgical therapy" OR "CIPO/intestinal transplantation." Only English language papers were included; the bibliographies of relevant papers were searched, including earlier papers.
